BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Patients First

Patients First

Individuals living with serious and debilitating chronic conditions often struggle with feelings of isolation. Because the effects are often individualized to the patient, the impact can easily be misunderstood or minimized by society—leaving patients feeling abandoned and alone. This is especially true for the more than 20 million individuals living with chronic, severe pain in the United States.

At BDSI, our mission extends beyond providing access to therapeutic solutions. We believe advocating for patients—being a voice for awareness and change—is an integral part of helping individuals make progress in their lives. This is who we are. This is how we put patients first.

This Is Pain

This Is Pain is a long-term initiative that aims to improve the lives of millions of American adults living with serious and debilitating chronic pain. This Is Pain seeks to first confront the stigma around the disease state, creating widespread awareness and empathy, to ultimately combat the systemic challenges those living with serious and debilitating chronic pain face. These challenges include experiencing unfair treatment in the workplace and difficulty in accessing affordable treatment options.

Learn more
Image of woman

"If you could see my pain, you would see the beautiful mask of my face, and under it, you would see every natural disaster happening at the same time."

"You can't judge a person just by looking at them. On the outside, they may look very normal and healthy, but on the inside, they may be experiencing a constant firestorm of pain."

Image of man

Recent BDSI News

May 29, 2020

RALEIGH, N.C. , May 29, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Interim Chief Executive

Read more
May 11, 2020

RALEIGH, N.C. , May 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey A.

Read more
May 7, 2020

First Quarter Total Company Net Sales Increased 94% versus Prior Year to $38.3 Million First Quarter BELBUCA® Net Sales Increased 79% versus Prior Year to $33.5 Million Conference Call and Webcast Scheduled for 4:30 PM EST Today RALEIGH, N.C. , May 07, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
July 2, 2020BDSI $4.44/ - 2.54%
Data provided by Nasdaq. Minimum 15 minutes delayed.